RLYB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rallybio Corp (RLYB) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of positive trading signals, weak financial performance, and absence of significant catalysts make it prudent to hold off on investing in this stock right now.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 28.791, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 8.505) in pre-market at 8.44, suggesting limited upside potential in the short term.
Revenue increased significantly by 484.21% YoY in Q4 2025, and gross margin remains strong at 100%.
Net income dropped by 47.01% YoY, and EPS declined by 47.98% YoY, reflecting poor profitability. No significant news or trading trends from hedge funds, insiders, or Congress. Technical indicators and stock trend analysis suggest limited immediate upside.
In Q4 2025, Rallybio Corp's revenue surged by 484.21% YoY to $222,000. However, net income dropped to -$5,852,000 (-47.01% YoY), and EPS fell to -1.03 (-47.98% YoY). Gross margin remained flat at 100%.
No data available on recent analyst ratings or price target changes.
